← Back to Search

Other

Cocktail Probe Substrates + BMS-986419 for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Bristol-Myers Squibb

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 28 days after last dose

Awards & highlights

Study Summary

This trial tests the effects of a drug on 6 common medicines in healthy people.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 28 days after last dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 28 days after last dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 28 days after last dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T))

Columbia-Suicide Severity Rating Scale (C-SSRS)

+8 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Cocktail Probe Substrates + BMS-986419Experimental Treatment7 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Fexofenadine

2016

Completed Phase 4

~940

BMS-986419

2023

Completed Phase 1

~30

Caffeine

2014

Completed Phase 3

~2980

Bupropion

2011

Completed Phase 4

~3310

Omeprazole

2006

Completed Phase 4

~940

Flurbiprofen

2022

Completed Phase 4

~870

Midazolam

2018

Completed Phase 4

~1910

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor

2,638 Previous Clinical Trials

4,128,492 Total Patients Enrolled

Media Library

BMS-986419 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05932277 — Phase 1

Healthy Subjects Research Study Groups: Cocktail Probe Substrates + BMS-986419

Healthy Subjects Clinical Trial 2023: BMS-986419 Highlights & Side Effects. Trial Name: NCT05932277 — Phase 1

BMS-986419 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05932277 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Am I eligible to get involved in this research?

"To qualify for this trial, candidates must be in good health and aged between 18 and 55. 22 participants are currently being recruited."

Answered by AI

Has the regulatory agency accepted Cocktail Probe Substrates + BMS-986419 for medical use?

"The safety of Cocktail Probe Substrates + BMS-986419 was judged to be a 1 on the scale from 1 to 3. This is mainly due to this being a Phase 1 trial, meaning that there are limited clinical studies supporting its efficacy and safety."

Answered by AI

Is the eligibility for this research project restricted to persons under 25 years of age?

"This medical research has a specific age bracket for participants; it requires that those enrolling be between 18 and 55 years old. However, there are other studies available to minors (under the age of 18) and elderly individuals (over 65)."

Answered by AI

Is there currently an opportunity for people to join the trial?

"Clinicaltrials.gov shows that, as of June 27th 2023, this medical trial is no longer seeking participants. The study's initial posting date was June 28th 2023 and it has since been closed to recruitment. Despite the cessation of participant intake for this particular experiment, 786 other trials are still actively searching for volunteers."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants

2023. "A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05932277.